Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +8.23% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $20.81 today, the market must believe free cash flow compounds 21.0%/yr for a decade (off $4M normalized FCF).
The market's 21.0% is more optimistic than its 9-yr track record.
2-stage DCF · 0.01B shares · net debt -$57M
mean -19.9% · volatility σ 132% · implied rate exceeded in 1/6 yrs
Central path = implied 21.0%/yr growth; shaded band = ±1σ (132%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $9M buybacks = $9M returned on $4M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $57M covers all $16M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2012-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M 100.0% | $119.9M 100.0% | $120.8M 100.0% | $113.8M 100.0% | $147.8M 100.0% | $130.5M 100.0% | $114.6M 100.0% | $105.6M 100.0% | $113.4M 100.0% | $103.4M 100.0% |
| Cost of Revenue | $49.0M 43.4% | $43.9M 36.6% | $38.3M 31.7% | $40.6M 35.7% | $64.9M 43.9% | $61.4M 47.1% | $28.7M 25.1% | $31.3M 29.6% | $27.4M 24.1% | $24.0M 23.2% |
| Cost of Products | — | — | — | — | — | — | — | — | $27.4M 24.1% | $24.0M 23.2% |
| Gross Profit | $63.8M 56.6% | $76.0M 63.4% | $82.5M 68.3% | $73.2M 64.3% | $82.9M 56.1% | $69.0M 52.9% | $85.9M 74.9% | $74.3M 70.4% | — | — |
| Research & Development | $25.8M 22.8% | $25.5M 21.3% | $21.8M 18.0% | $18.3M 16.1% | $27.3M 18.5% | $23.4M 18.0% | $16.7M 14.5% | $18.2M 17.2% | $18.8M 16.6% | $10.7M 10.4% |
| Selling, General & Admin | $49.1M 43.5% | $55.6M 46.3% | $59.9M 49.6% | $51.2M 45.0% | $74.1M 50.1% | $60.1M 46.0% | $35.0M 30.5% | $34.3M 32.5% | $21.5M 19.0% | $18.0M 17.4% |
| Total Operating Expenses | $74.9M 66.4% | $81.1M 67.6% | $81.7M 67.6% | $69.5M 61.1% | $80.3M 54.4% | $97.3M 74.6% | $51.6M 45.0% | $52.5M 49.8% | $67.7M 59.7% | $52.8M 51.0% |
| Operating Income | -$11.1M -9.8% | -$5.1M -4.3% | $844K 0.7% | $3.7M 3.2% | $2.6M 1.8% | -$28.3M -21.7% | $34.2M 29.9% | $21.7M 20.6% | $45.7M 40.3% | $50.6M 49.0% |
| Pretax Income | -$9.3M -8.2% | -$2.8M -2.3% | $3.2M 2.6% | $4.3M 3.8% | $2.4M 1.6% | -$28.6M -21.9% | $36.1M 31.5% | $23.2M 22.0% | $46.2M 40.7% | $50.9M 49.2% |
| Income Tax Expense | $672K 0.6% | $6.1M 5.1% | $6.6M 5.5% | $2.1M 1.9% | -$1.7M -1.2% | -$4.6M -3.6% | $8.9M 7.8% | $4.5M 4.2% | $14.4M 12.7% | $18.3M 17.7% |
| Net Income | -$11.0M -9.8% | -$56.0M -46.7% | -$83.0M -68.7% | -$15.0M -13.2% | $4.0M 2.7% | -$24.0M -18.4% | $27.2M 23.7% | $18.7M 17.7% | $31.8M 28.1% | $32.5M 31.5% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.29 | $-1.69 | $1.93 | $1.30 | $2.18 | $2.22 |
| EPS (Diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
| Weighted Avg Shares (Basic) | 14.3M | 14.7M | 14.7M | 14.6M | 14.4M | 14.2M | 14.1M | 14.4M | 14.6M | 14.7M |
| Weighted Avg Shares (Diluted) | 14.3M | 14.7M | 14.7M | 14.8M | 14.6M | 14.2M | 14.4M | 14.7M | 15.1M | 15.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-18
Where each multiple sits in its own 14-yr range · 36th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 29.6 | 25.1 | 47.1 | 43.9 | 35.7 | 31.7 | 36.6 | 43.4 |
| Gross Profit | 70.4 | 74.9 | 52.9 | 56.1 | 64.3 | 68.3 | 63.4 | 56.6 |
| R&D | 17.2 | 14.5 | 18.0 | 18.5 | 16.1 | 18.0 | 21.3 | 22.8 |
| SG&A | 32.5 | 30.5 | 46.0 | 50.1 | 45.0 | 49.6 | 46.3 | 43.5 |
| Operating Income | 20.6 | 29.9 | -21.7 | 1.8 | 3.2 | 0.7 | -4.3 | -9.8 |
| Income Tax | 4.2 | 7.8 | -3.6 | -1.2 | 1.9 | 5.5 | 5.1 | 0.6 |
| Net Income | 17.7 | 23.7 | -18.4 | 2.7 | -13.2 | -68.7 | -46.7 | -9.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ANIK: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ANIK | $292M | — | — | 2.6× | -5.9% | 56.6% | -9.6% | -7.6% | -7.6% | — | 123 |
Peers = companies sharing ANIK's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.